Första AP-fonden’s Novavax NVAX Stock Holding History

Första AP-fonden’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,000	Closed	-$103K	–	609
2022 Q2	$103K	Buy	+2,000	New	+$104K	﹤0.01%	589
2021 Q3	–	Sell	-15,800	Closed	-$3.35M	–	566
2021 Q2	$3.35M	Buy	+15,800	New	+$2.89M	0.04%	461

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Första AP-fonden's NVAX Position: Q3 2022 in Review

Första AP-fonden sold out of Novavax (NVAX) in Q3 2022, closing a stake of 2,000 shares — an estimated $103K sold.

Första AP-fonden first reported a position in NVAX in Q2 2021 and held it in 2 quarters. The position peaked at $3.35M in Q2 2021. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

Första AP-fonden reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
Första AP-fonden sold 2,000 Novavax shares in Q3 2022, an estimated $103K.
Första AP-fonden first reported a position in Novavax in Q2 2021 and held it in 2 quarters.
Första AP-fonden's Novavax position peaked at $3.35M in Q2 2021.
253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Första AP-fonden's 13F filing for Q3 2022, filed 17 Oct 2022.